Trial Design
MCI, Dementia
A Trial of Cilostazol for Prevention of Conversion from MCI to Dementia (COMCID) was a phase 2, investigator-initiated, double-blind randomized clinical trial, approved by the Institutional Review Board of the National Cerebral and Cardiovascular Center, Suita, Japan, and 14 other participating hospitals. Written informed consent was obtained from all patients. We followed the Consolidated Standards of Reporting Trials (